AI assistant
CRANEWARE PLC Board/Management Information 2020
7581_mang_2020-11-26_1a4f3781-dfad-48cc-83f9-ae38971bb001.html
Board/Management Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 5440G
Craneware plc
26 November 2020
Craneware plc
("Craneware" or "the Company")
Appointment of Joint Broker
26 November 2020 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle software solutions for the US healthcare market, is pleased to announce the appointment of Berenberg as joint broker with immediate effect, alongside Peel Hunt and Investec Bank. Peel Hunt remains the Company's Nominated Adviser.
For further information, please contact:
| Craneware plc | Peel Hunt NOMAD & Joint Broker |
Investec Bank Joint Broker |
Berenberg Joint Broker |
Alma Financial PR |
| +44 (0)131 550 3100 | +44 (0)20 7418 8900 | +44 (0)20 7597 5970 | +44 (0) 20 3207 7800 | +44 (0)203 405 0205 |
| Keith Neilson, CEO | Dan Webster | Patrick Robb | Mark Whitmore | Caroline Forde |
| Craig Preston, CFO | George Sellar | Sebastian Lawrence | Richard Salmond | Robyn Fisher |
| Andrew Clark | Henry Reast | Alix Mecklenberg- | Helena Bogle | |
| Solodkoff | Joe Pederzolli |
About Craneware
Craneware (AIM: CRW.L), the leader in automated value cycle solutions, collaborates with U.S. healthcare providers to plan, execute and monitor value-based economic performance. Founded in 1999, Craneware is headquartered in Edinburgh, Scotland with offices in Atlanta and Pittsburgh employing over 350 staff. Craneware's value cycle management suite includes charge capture, strategic pricing, patient engagement, claims analytics, revenue recovery and retention, and cost and margin intelligence solutions.
Learn more at www.craneware.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
APPBABLTMTMTBFM